Celator Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Celator Pharmaceuticals, Inc. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include VYXEOS, CELATOR, and COMBIPLEX. The owner is based in Ewing, NJ.
Suite 180
200 Princeton South Corporate Center
Ewing, NJ 08628
Showing of trademarks Trademarks
Trademark Classifications
Celator Pharmaceuticals, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Celator Pharmaceuticals, Inc. have?
Celator Pharmaceuticals, Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 5 registered, 3 abandoned, 2 cancelled.
What trademark classes does Celator Pharmaceuticals, Inc. file in?
Celator Pharmaceuticals, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Celator Pharmaceuticals, Inc.'s most well-known trademarks?
Celator Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as VYXEOS, CELATOR, and COMBIPLEX. These are among 5 currently registered trademarks in the portfolio.
What is Celator Pharmaceuticals, Inc.'s trademark registration success rate?
Celator Pharmaceuticals, Inc. has a 50% trademark registration rate, with 5 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.